• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

高通量筛选和机器学习探索纳米医学设计空间。

Exploration of the nanomedicine-design space with high-throughput screening and machine learning.

机构信息

Interdisciplinary Biological Sciences Graduate Program, Northwestern University, Evanston, IL, USA.

International Institute for Nanotechnology, Northwestern University, Evanston, IL, USA.

出版信息

Nat Biomed Eng. 2019 Apr;3(4):318-327. doi: 10.1038/s41551-019-0351-1. Epub 2019 Feb 18.

DOI:10.1038/s41551-019-0351-1
PMID:30952978
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6452897/
Abstract

Only a tiny fraction of the nanomedicine-design space has been explored, owing to the structural complexity of nanomedicines and the lack of relevant high-throughput synthesis and analysis methods. Here, we report a methodology for determining structure-activity relationships and design rules for spherical nucleic acids (SNAs) functioning as cancer-vaccine candidates. First, we identified ~1,000 candidate SNAs on the basis of reasonable ranges for 11 design parameters that can be systematically and independently varied to optimize SNA performance. Second, we developed a high-throughput method for making SNAs at the picomolar scale in a 384-well format, and used a mass spectrometry assay to rapidly measure SNA immune activation. Third, we used machine learning to quantitatively model SNA immune activation and identify the minimum number of SNAs needed to capture optimum structure-activity relationships for a given SNA library. Our methodology is general, can reduce the number of nanoparticles that need to be tested by an order of magnitude, and could serve as a screening tool for the development of nanoparticle therapeutics.

摘要

由于纳米药物的结构复杂性以及缺乏相关的高通量合成和分析方法,目前仅探索了纳米医学设计空间的一小部分。在这里,我们报告了一种用于确定作为癌症疫苗候选物的球形核酸 (SNA) 的结构-活性关系和设计规则的方法。首先,我们根据可以系统且独立地改变以优化 SNA 性能的 11 个设计参数的合理范围,确定了~1000 个候选 SNA。其次,我们开发了一种在 384 孔格式中以皮摩尔级规模制备 SNA 的高通量方法,并使用质谱分析快速测量 SNA 免疫激活。第三,我们使用机器学习对 SNA 免疫激活进行定量建模,并确定给定 SNA 文库中捕获最佳结构-活性关系所需的最少 SNA 数量。我们的方法具有通用性,可以将需要测试的纳米颗粒数量减少一个数量级,并且可以作为纳米颗粒治疗药物开发的筛选工具。

相似文献

1
Exploration of the nanomedicine-design space with high-throughput screening and machine learning.高通量筛选和机器学习探索纳米医学设计空间。
Nat Biomed Eng. 2019 Apr;3(4):318-327. doi: 10.1038/s41551-019-0351-1. Epub 2019 Feb 18.
2
Immunomodulatory spherical nucleic acids.免疫调节球形核酸
Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):3892-7. doi: 10.1073/pnas.1502850112. Epub 2015 Mar 16.
3
Backbone-modified oligonucleotides for tuning the cellular uptake behaviour of spherical nucleic acids.用于调节球形核酸细胞摄取行为的骨架修饰寡核苷酸。
Biomater Sci. 2017 Feb 28;5(3):412-416. doi: 10.1039/c6bm00792a.
4
Applications of Spherical Nucleic Acid Nanoparticles as Delivery Systems.球形核酸纳米粒子作为递药系统的应用。
Trends Mol Med. 2019 Dec;25(12):1066-1079. doi: 10.1016/j.molmed.2019.08.012. Epub 2019 Nov 6.
5
In Vivo Behavior of Ultrasmall Spherical Nucleic Acids.超小球形核酸的体内行为。
Small. 2023 Jun;19(24):e2300097. doi: 10.1002/smll.202300097. Epub 2023 Mar 11.
6
Intracellular fate of spherical nucleic acid nanoparticle conjugates.球形核酸纳米颗粒缀合物的细胞内命运
J Am Chem Soc. 2014 May 28;136(21):7726-33. doi: 10.1021/ja503010a. Epub 2014 May 19.
7
Sequence Multiplicity within Spherical Nucleic Acids.球形核酸内的序列重复度。
ACS Nano. 2020 Jan 28;14(1):1084-1092. doi: 10.1021/acsnano.9b08750. Epub 2020 Jan 9.
8
Tumor-Associated Enzyme-Activatable Spherical Nucleic Acids.肿瘤相关酶激活的球形核酸
ACS Nano. 2022 Jul 26;16(7):10931-10942. doi: 10.1021/acsnano.2c03323. Epub 2022 Jul 18.
9
Synthesis, Physicochemical, and Biological Evaluation of Spherical Nucleic Acids for RNAi-Based Therapy in Glioblastoma.用于胶质母细胞瘤基于RNA干扰疗法的球形核酸的合成、物理化学及生物学评价
Methods Mol Biol. 2019;1974:371-391. doi: 10.1007/978-1-4939-9220-1_25.
10
Spherical Nucleic Acids as Precision Therapeutics for the Treatment of Cancer-From Bench to Bedside.球形核酸作为癌症治疗的精准疗法——从实验室到临床应用
Cancers (Basel). 2022 Mar 23;14(7):1615. doi: 10.3390/cancers14071615.

引用本文的文献

1
Recent Advances in Nanomedicine: Cutting-Edge Research on Nano-PROTAC Delivery Systems for Cancer Therapy.纳米医学的最新进展:用于癌症治疗的纳米PROTAC递送系统的前沿研究
Pharmaceutics. 2025 Aug 10;17(8):1037. doi: 10.3390/pharmaceutics17081037.
2
The emerging era of structural nanomedicine.结构纳米医学的崭新时代。
Nat Rev Bioeng. 2025 Jul;3(7):526-528. doi: 10.1038/s44222-025-00306-5. Epub 2025 Apr 25.
3
Eliciting antitumor immunity via therapeutic cancer vaccines.通过治疗性癌症疫苗激发抗肿瘤免疫力。

本文引用的文献

1
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date.基于纳米颗粒的药物:对美国食品药品监督管理局(FDA)批准的材料及迄今临床试验的综述。
Pharm Res. 2016 Oct;33(10):2373-87. doi: 10.1007/s11095-016-1958-5. Epub 2016 Jun 14.
2
Cellular Assays with a Molecular Endpoint Measured by SAMDI Mass Spectrometry.采用表面增强常压解吸质谱法测量分子终点的细胞分析
Small. 2016 Jul;12(28):3811-8. doi: 10.1002/smll.201502940. Epub 2016 May 30.
3
Immunomodulatory spherical nucleic acids.免疫调节球形核酸
Cell Mol Immunol. 2025 Jul 9. doi: 10.1038/s41423-025-01316-4.
4
Machine Learning-Enhanced Nanoparticle Design for Precision Cancer Drug Delivery.用于精准癌症药物递送的机器学习增强型纳米颗粒设计
Adv Sci (Weinh). 2025 Aug;12(30):e03138. doi: 10.1002/advs.202503138. Epub 2025 Jun 19.
5
Blueprints for Better Drugs: The Structural Revolution in Nanomedicine.更好药物的蓝图:纳米医学的结构革命
ACS Nano. 2025 May 27;19(20):18889-18901. doi: 10.1021/acsnano.5c06380. Epub 2025 May 13.
6
Nanomedicines Targeting Metabolic Pathways in the Tumor Microenvironment: Future Perspectives and the Role of AI.靶向肿瘤微环境中代谢途径的纳米药物:未来展望与人工智能的作用
Metabolites. 2025 Mar 13;15(3):201. doi: 10.3390/metabo15030201.
7
Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.小核酸疗法全景:作为下一代药物从实验室走向临床
Signal Transduct Target Ther. 2025 Mar 10;10(1):73. doi: 10.1038/s41392-024-02112-8.
8
Machine learning-assisted design of immunomodulatory lipid nanoparticles for delivery of mRNA to repolarize hyperactivated microglia.用于递送mRNA以重新极化过度活化小胶质细胞的免疫调节脂质纳米颗粒的机器学习辅助设计
Drug Deliv. 2025 Dec;32(1):2465909. doi: 10.1080/10717544.2025.2465909. Epub 2025 Mar 3.
9
Deep Learning Predicts Non-Normal Transmission Distributions in High-Field Asymmetric Waveform Ion Mobility (FAIMS) Directly from Peptide Sequence.深度学习直接从肽序列预测高场不对称波形离子迁移谱(FAIMS)中的非正态传输分布。
Anal Chem. 2025 Feb 4;97(4):2254-2263. doi: 10.1021/acs.analchem.4c05359. Epub 2025 Jan 26.
10
Pioneering integration of combinatorial chemistry and machine learning to accelerate the development of tailored LNPs for mRNA delivery.开创性地将组合化学与机器学习相结合,以加速用于mRNA递送的定制脂质纳米颗粒的开发。
Acta Pharm Sin B. 2024 Nov;14(11):5079-5081. doi: 10.1016/j.apsb.2024.08.032. Epub 2024 Sep 2.
Proc Natl Acad Sci U S A. 2015 Mar 31;112(13):3892-7. doi: 10.1073/pnas.1502850112. Epub 2015 Mar 16.
4
Phosphorothioate backbone modifications of nucleotide-based drugs are potent platelet activators.基于核苷酸的药物的硫代磷酸酯主链修饰是强效的血小板激活剂。
J Exp Med. 2015 Feb 9;212(2):129-37. doi: 10.1084/jem.20140391. Epub 2015 Feb 2.
5
Liposomal spherical nucleic acids.脂质体球形核酸
J Am Chem Soc. 2014 Jul 16;136(28):9866-9. doi: 10.1021/ja504845f. Epub 2014 Jul 1.
6
Mechanism for the endocytosis of spherical nucleic acid nanoparticle conjugates.球形核酸纳米颗粒缀合物内吞作用的机制。
Proc Natl Acad Sci U S A. 2013 May 7;110(19):7625-30. doi: 10.1073/pnas.1305804110. Epub 2013 Apr 23.
7
Spherical nucleic acids.球形核酸。
J Am Chem Soc. 2012 Jan 25;134(3):1376-91. doi: 10.1021/ja209351u. Epub 2012 Jan 9.
8
Selective enhancement of nucleases by polyvalent DNA-functionalized gold nanoparticles.多价 DNA 功能化金纳米粒子对核酸酶的选择性增强。
J Am Chem Soc. 2011 Feb 23;133(7):2120-3. doi: 10.1021/ja110833r. Epub 2011 Jan 26.
9
Mass spectrometry of self-assembled monolayers: a new tool for molecular surface science.自组装单分子层的质谱分析:分子表面科学的一种新工具。
ACS Nano. 2008 Jan;2(1):7-18. doi: 10.1021/nn7004156.
10
Polyvalent DNA nanoparticle conjugates stabilize nucleic acids.多价DNA纳米颗粒缀合物可稳定核酸。
Nano Lett. 2009 Jan;9(1):308-11. doi: 10.1021/nl802958f.